Cargando…
Minimal Physiologically-Based Pharmacokinetic (mPBPK) Metamodeling of Target Engagement in Skin Informs Anti-IL17A Drug Development in Psoriasis
The pharmacologic effect(s) of biotherapeutics directed against soluble targets are driven by the magnitude and duration of free target suppression at the tissue site(s) of action. Interleukin (IL)-17A is an inflammatory cytokine that plays a key role in the pathogenesis of psoriasis. In this work,...
Autores principales: | Ayyar, Vivaswath S., Lee, Jong Bong, Wang, Weirong, Pryor, Meghan, Zhuang, Yanli, Wilde, Thomas, Vermeulen, An |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9083543/ https://www.ncbi.nlm.nih.gov/pubmed/35548359 http://dx.doi.org/10.3389/fphar.2022.862291 |
Ejemplares similares
-
ATLAS mPBPK: A MATLAB‐Based Tool for Modeling and Simulation of Minimal Physiologically‐Based Pharmacokinetic Models
por: Mavroudis, Panteleimon D., et al.
Publicado: (2019) -
Development of a Minimalistic Physiologically Based Pharmacokinetic (mPBPK) Model for the Preclinical Development of Spectinamide Antibiotics
por: Parmar, Keyur R., et al.
Publicado: (2023) -
1388. Dose Discrimination for ASN100: Bridging from Rabbit Survival Data to Predicted Activity in Humans Using a Minimal Physiologically Based Pharmacokinetic (mPBPK) Model
por: Rubino, Christopher M, et al.
Publicado: (2018) -
The simulation metamodel
por: Friedman, Linda Weiser
Publicado: (1996) -
Metamodelling for software engineering
por: Gonzalez Perez, Cesar, et al.
Publicado: (2008)